Furthermore, metabolomics has also been used for predicting the development of neutralizing anti-drug antibodies in MS patients treated with IFN-β, which contributes to predicting the immunogenicity against IFN-β (Waddington et al., 2020) associated with the loss of treatment efficacy. This evidence concerns the gene IFNB1 and myeloid sarcoma.